Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts (Nasdaq: TMCI) has announced participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 am ET. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat. The event aims to highlight Treace's advancements in treating hallux valgus (bunions) through their patented Lapiplasty® 3D Bunion Correction™ system and the recently introduced Adductoplasty™ Midfoot Correction System, which addresses complex foot deformities and enhances patient recovery.
Treace Medical Concepts (TMCI) reported Q3 2021 revenue of $21.6 million, marking a 52% increase year-over-year and a 4.7% sequential rise. The gross margin improved to 80.4%, up 80 basis points from the previous year. Key developments included the launch of the Adductoplasty™ System and positive interim data from the ALIGN3D™ clinical study, which showed low recurrence rates post-surgery. Despite pandemic challenges, the firm reaffirms its 2021 revenue guidance of $90 million to $95 million, projecting 57% to 65% growth over 2020.
Treace Medical Concepts (TMCI) announced the granting of U.S. Patent No. 11,147,590 for its bunion surgery method on October 19, 2021, enhancing its patent coverage in bunion correction techniques. This marks the company's 30th U.S. patent, expanding its innovative portfolio initiated in 2014. The new patent complements U.S. Patent No. 10,945,764, granted in March 2021. Treace’s ongoing R&D efforts aim to address patient needs, with over 60 pending patent applications globally, including over 30 in the U.S.
Treace Medical Concepts (TMCI) has announced the release date for its financial results for Q3 2021, scheduled for November 4, 2021, after the trading day ends. A conference call will follow at 4:30 p.m. ET to discuss the financials. Treace, which specializes in orthopaedic devices for bunion treatment, features the patented Lapiplasty® 3D Bunion Correction™ system, aimed at addressing the root causes of bunions and improving patient recovery. An archived webcast of the call will be available on their investor relations website.
Treace Medical Concepts (TMCI) announced the appointments of Betsy Hanna and Deepti Jain to its Board of Directors as of October 1, 2021. With extensive healthcare experience, both aim to guide the company through its growth phase, particularly focusing on the Lapiplasty® system and the new Adductoplasty™ Midfoot Correction System. Chairman James T. Treace expressed confidence in their ability to enhance the board's expertise and drive market penetration.
Treace Medical Concepts (TMCI) has initiated the Mini3D Lapiplasty clinical study, focusing on the Lapiplasty Mini-Incision System for bunion correction. The study aims to evaluate outcomes based on 3D correction with smaller incisions (3.5cm) compared to traditional methods. The primary measure of success will be the recurrence of hallux valgus within 24 months. The study will involve up to 200 patients across 20 centers, building on the previous ALIGN3D study, which has enrolled 173 patients and will conclude in 2023.
Treace Medical Concepts (TMCI) announced positive interim findings from the ALIGN3D™ clinical study on their Lapiplasty® 3D Bunion Correction™ procedure at the 2021 AOFAS Annual Meeting. The study, involving 151 participants, reported an average early weight-bearing return at 8.3 days, significant pain reduction, and a low recurrence rate of only 0.9% at 12 months. Patients also returned to work within 4 weeks and full activity within 4.1 months. Treace continues to strengthen its clinical evidence supporting the Lapiplasty® System, aimed at enhancing bunion surgery outcomes.
Treace Medical Concepts (TMCI) has launched the Adductoplasty™ System, a comprehensive approach for midfoot deformity correction in bunion patients. This system combines implants and precision instruments to ensure consistent realignment and stabilization of the midfoot, which affects up to 30% of hallux valgus cases. CEO John T. Treace highlighted the system's potential to enhance treatment for patients with combined bunion and midfoot issues, addressing a market gap in surgical solutions.
Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark Hair will join a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at approximately 4:15 PM ET. This discussion will focus on the company’s innovative Lapiplasty® 3D Bunion Correction™ procedure, designed to improve surgical treatment for bunions. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.